Cargando…

Identification of biomarkers for immunotherapy response in prostate cancer and potential drugs to alleviate immunosuppression

Background: Immunotherapy has a significant effect on the treatment of many tumor types. However, prostate cancers generally fail to show significant responses to immunotherapy owing to their immunosuppressive microenvironments. To sustain progress towards more effective immunotherapy for prostate c...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jinpeng, Ding, Xiaohui, Peng, Kun, Jia, Zhankui, Yang, Jinjian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9217695/
https://www.ncbi.nlm.nih.gov/pubmed/35680563
http://dx.doi.org/10.18632/aging.204115
_version_ 1784731708272148480
author Zhang, Jinpeng
Ding, Xiaohui
Peng, Kun
Jia, Zhankui
Yang, Jinjian
author_facet Zhang, Jinpeng
Ding, Xiaohui
Peng, Kun
Jia, Zhankui
Yang, Jinjian
author_sort Zhang, Jinpeng
collection PubMed
description Background: Immunotherapy has a significant effect on the treatment of many tumor types. However, prostate cancers generally fail to show significant responses to immunotherapy owing to their immunosuppressive microenvironments. To sustain progress towards more effective immunotherapy for prostate cancer, comprehensive analyses of the genetic characteristics of the immune microenvironment and novel therapeutic strategies are required. Methods: The transcriptome profiles of patients with prostate cancer were obtained from GEO and processed with the TIDE algorithm to predict their responses to immunotherapy. Next, the significant differentially expressed genes (DEGs) between the responder and non-responder groups were identified and used to compute the co-expression modules by WGCNA. Then, co-expression networks were constructed and survival analysis was applied to hub genes. Finally, drug candidates to alleviate immunosuppression were filtered in prostate cancer using GSEA based on hub genes. Results: In total, we identified 2758 significant DEGs and constructed 16 co-expression modules, seven of which were significantly correlated with the immune response score. In total, 133 hub genes were identified, of which 13 were significantly associated with prostate cancer prognosis. Co-expression networks of hub genes were constructed with KMT2B at the center. Finally, six candidate drugs for prostate cancer immunotherapy were identified in PC3 and LNCaP cell lines. Conclusions: We obtained datasets from multiple platforms, performed integrated bioinformatic analysis to identify 133 hub genes and 13 biomarkers of an immunotherapy response, and six candidate drugs were filtered to inhibit the immunosuppressive tumor microenvironment, to ultimately improve patient responses to immunotherapy in prostate cancer.
format Online
Article
Text
id pubmed-9217695
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Impact Journals
record_format MEDLINE/PubMed
spelling pubmed-92176952022-06-24 Identification of biomarkers for immunotherapy response in prostate cancer and potential drugs to alleviate immunosuppression Zhang, Jinpeng Ding, Xiaohui Peng, Kun Jia, Zhankui Yang, Jinjian Aging (Albany NY) Research Paper Background: Immunotherapy has a significant effect on the treatment of many tumor types. However, prostate cancers generally fail to show significant responses to immunotherapy owing to their immunosuppressive microenvironments. To sustain progress towards more effective immunotherapy for prostate cancer, comprehensive analyses of the genetic characteristics of the immune microenvironment and novel therapeutic strategies are required. Methods: The transcriptome profiles of patients with prostate cancer were obtained from GEO and processed with the TIDE algorithm to predict their responses to immunotherapy. Next, the significant differentially expressed genes (DEGs) between the responder and non-responder groups were identified and used to compute the co-expression modules by WGCNA. Then, co-expression networks were constructed and survival analysis was applied to hub genes. Finally, drug candidates to alleviate immunosuppression were filtered in prostate cancer using GSEA based on hub genes. Results: In total, we identified 2758 significant DEGs and constructed 16 co-expression modules, seven of which were significantly correlated with the immune response score. In total, 133 hub genes were identified, of which 13 were significantly associated with prostate cancer prognosis. Co-expression networks of hub genes were constructed with KMT2B at the center. Finally, six candidate drugs for prostate cancer immunotherapy were identified in PC3 and LNCaP cell lines. Conclusions: We obtained datasets from multiple platforms, performed integrated bioinformatic analysis to identify 133 hub genes and 13 biomarkers of an immunotherapy response, and six candidate drugs were filtered to inhibit the immunosuppressive tumor microenvironment, to ultimately improve patient responses to immunotherapy in prostate cancer. Impact Journals 2022-06-08 /pmc/articles/PMC9217695/ /pubmed/35680563 http://dx.doi.org/10.18632/aging.204115 Text en Copyright: © 2022 Zhang et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Zhang, Jinpeng
Ding, Xiaohui
Peng, Kun
Jia, Zhankui
Yang, Jinjian
Identification of biomarkers for immunotherapy response in prostate cancer and potential drugs to alleviate immunosuppression
title Identification of biomarkers for immunotherapy response in prostate cancer and potential drugs to alleviate immunosuppression
title_full Identification of biomarkers for immunotherapy response in prostate cancer and potential drugs to alleviate immunosuppression
title_fullStr Identification of biomarkers for immunotherapy response in prostate cancer and potential drugs to alleviate immunosuppression
title_full_unstemmed Identification of biomarkers for immunotherapy response in prostate cancer and potential drugs to alleviate immunosuppression
title_short Identification of biomarkers for immunotherapy response in prostate cancer and potential drugs to alleviate immunosuppression
title_sort identification of biomarkers for immunotherapy response in prostate cancer and potential drugs to alleviate immunosuppression
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9217695/
https://www.ncbi.nlm.nih.gov/pubmed/35680563
http://dx.doi.org/10.18632/aging.204115
work_keys_str_mv AT zhangjinpeng identificationofbiomarkersforimmunotherapyresponseinprostatecancerandpotentialdrugstoalleviateimmunosuppression
AT dingxiaohui identificationofbiomarkersforimmunotherapyresponseinprostatecancerandpotentialdrugstoalleviateimmunosuppression
AT pengkun identificationofbiomarkersforimmunotherapyresponseinprostatecancerandpotentialdrugstoalleviateimmunosuppression
AT jiazhankui identificationofbiomarkersforimmunotherapyresponseinprostatecancerandpotentialdrugstoalleviateimmunosuppression
AT yangjinjian identificationofbiomarkersforimmunotherapyresponseinprostatecancerandpotentialdrugstoalleviateimmunosuppression